Shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) traded down 6.4% during trading on Wednesday . The company traded as low as $17.66 and last traded at $17.68. 629,705 shares were traded during trading, an increase of 15% from the average session volume of 546,406 shares. The stock had previously closed at $18.89.
A number of analysts have recently commented on the company. ValuEngine downgraded Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Zacks Investment Research downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. BidaskClub downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 5th. Finally, BMO Capital Markets upped their price objective on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a report on Tuesday, November 7th. Three equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $64.00.
The stock has a market cap of $601.31, a price-to-earnings ratio of -3.49 and a beta of 3.56.
A number of hedge funds and other institutional investors have recently made changes to their positions in FPRX. Teacher Retirement System of Texas acquired a new stake in Five Prime Therapeutics in the 4th quarter valued at $221,000. Oppenheimer & Co. Inc. acquired a new stake in Five Prime Therapeutics in the 3rd quarter valued at $223,000. MetLife Investment Advisors LLC acquired a new stake in Five Prime Therapeutics in the 4th quarter valued at $294,000. Dupont Capital Management Corp acquired a new stake in Five Prime Therapeutics in the 3rd quarter valued at $341,000. Finally, Voya Investment Management LLC increased its holdings in Five Prime Therapeutics by 9.5% in the 2nd quarter. Voya Investment Management LLC now owns 12,594 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 1,097 shares in the last quarter. Hedge funds and other institutional investors own 73.98% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Five Prime Therapeutics (FPRX) Trading Down 6.4%” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/02/21/five-prime-therapeutics-fprx-trading-down-6-4.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.